Osteotech in a public battle over control |

Osteotech in a public battle over control

Osteotech girds for rumble with dissident investors (MassDevice)

Unhappy Investors cite:
  • poor performance and 28% stock loss under CEO Sam Owusa-Akyaw
  • $4M loss in 2009
  • passed up on 2005 acquisition offer from MTF
  • loss a major private-label contract with Smith & Nephew

Leave a Reply

Your email address will not be published. Required fields are marked *